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Background: Following the 2013 USA release of the Influenza Virologic Surveillance 
Right Size Roadmap, the New York State Department of Health (NYSDOH) embarked 
on an evaluation of data sources for influenza virologic surveillance.
Objective: To assess NYS data sources, additional to data generated by the state pub-
lic health laboratory (PHL), which could enhance influenza surveillance at the state and 
national level.
Methods: Potential sources of laboratory test data for influenza were analyzed for 
quantity and quality. Computer models, designed to assess sample sizes and the con-
fidence of data for statistical representation of influenza activity, were used to com-
pare PHL test data to results from clinical and commercial laboratories, reported 
between June 8, 2013 and May 31, 2014.
Results: Sample sizes tested for influenza at the state PHL were sufficient for situa-
tional awareness surveillance with optimal confidence levels, only during peak weeks 
of the influenza season. Influenza data pooled from NYS PHLs and clinical laboratories 
generated optimal confidence levels for situational awareness throughout the influ-
enza season. For novel influenza virus detection in NYS, combined real- time (rt) RT- 
PCR data from state and regional PHLs achieved ≥85% confidence during peak 
influenza activity, and ≥95% confidence for most of low season and all of off- season.
Conclusions: In NYS, combined data from clinical, commercial, and public health labo-
ratories generated optimal influenza surveillance for situational awareness throughout 
the season. Statistical confidence for novel virus detection, which is reliant on only 
PHL data, was achieved for most of the year.
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1  | INTRODUCTION
Influenza surveillance is essential to monitor the spread and severity 
of the disease, identify populations at risk, detect the emergence of 
new subtypes and variant strains with pandemic potential, monitor the 
prevalence of drug resistance, characterize circulating virus types for 
the selection of strains for vaccine production, and provide information 
and guidance for clinicians and public health officials. The World Health 
Organization (WHO) established a global surveillance network for dis-
ease caused by influenza viruses in 1952.1 Since then, the Centers for 
Disease Control and Prevention (CDC) in collaboration with a network 
of PHLs has formed a US national influenza surveillance system com-
prising 85 PHLs performing molecular assays from the CDC to type 
and subtype the influenza virus, and 60 hospital laboratories reporting 
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influenza test data.2 The consequent network and data monitoring 
systems have facilitated the detection of numerous important events 
and viral changes, including the rapid identification in 2009 of the pan-
demic influenza strain (A/H1pdm09). In 2010, to address concurrent 
fiscal constraints and emerging diseases, the CDC and the Association 
of Public Health Laboratories (APHL) initiated the Influenza Virologic 
Surveillance Right Size Project to assess the vast and complex national 
surveillance system, determine the most efficient means to monitor 
influenza activity, and establish a standard reference for the CDC and 
state PHLs.2 The Influenza Virologic Surveillance Right Size Roadmap 
(1st Edition released in 2013) attempted to guide surveillance toward 
a more systematic and statistically relevant process. The roadmap in-
cludes sample size calculators, developed to estimate the appropriate 
numbers of samples needed to achieve influenza surveillance with sta-
tistical confidence for situational awareness and rare/novel influenza 
event detection. The roadmap proposed identification of alternate, 
non- PHL, data sources as a means to augment state PHL data and, in 
turn, enhance national surveillance.
Data generated from the NYS PHL, the Wadsworth Center, were 
measured against sample numbers calculated with the computer mod-
els for influenza situational awareness and rare/novel event detection. 
New York State alternate data from clinical and commercial labora-
tories were analyzed for integrity and impact on influenza situational 
awareness. Regional NYS PHL data were assessed for its impact on 
rare/novel event detection. New York State Department of Health sci-
entific staff in the Virology Laboratory at the Wadsworth Center, in 
partnership with epidemiologists from the Bureau of Communicable 
Disease Control (BCDC), evaluated influenza testing practices, regula-
tions, infrastructure, data collection, and reporting. Additionally, sur-
veillance policy, potential future ideal practices and systems, and likely 
hurdles that may impede implementation were discussed.
2  | METHODS
2.1 | Situational awareness of influenza viral disease 
in NYS
2.1.1 | Laboratory networks of influenza 
data sources
The NYS Wadsworth Center PHL performs influenza testing on speci-
mens received through the Influenza- like Illness Network (ILINet) and 
Emerging Infections Program (EIP), in addition to samples received 
from non- EIP hospitals, student health clinics, veteran administration 
(VA) centers, long- term care facilities, correctional facilities, and oc-
casionally commercial laboratories.
The ILINet is an outpatient influenza surveillance program sup-
ported by CDC in all states.3 For the 2013- 2014 season, the NYSDOH 
ILINet Program had 173 participating primary care physicians (ILINet 
providers) in 39 of the 57 NYS counties outside of New York City, from 
a variety of medical practice specialties 4 (Figure 1). ILINet providers 
report data and submit specimens from patients with medically at-
tended influenza- like illness (MA- ILI). The New York City Department 
of Health and Mental Hygiene (NYCDOHMH) coordinates a separate 
ILINet Program in the five counties of NYC.
The CDC supports the EIP, a program within FluServ- NET,3 for 
surveillance of patients hospitalized with influenza. The influenza ac-
tivities component of EIP in NYS comprises 21 hospitals in 15 counties 
around Albany in the Capital District region and Rochester in west-
ern NYS. Participating hospitals send a subset of data and influenza- 
positive samples to the Wadsworth Center for confirmation and virus 
characterization.
The Wadsworth Center is both a WHO Collaborating Laboratory 
and a National Respiratory and Enteric Virus Surveillance System 
(NREVSS) laboratory. The 11 WHO and 11 NREVSS clinical labora-
tories in NYS (including four which are both) voluntarily participate in 
these networks and transmit influenza surveillance data to the CDC.3
2.1.2 | Sample size calculators
The Influenza Virologic Surveillance Right Size Project developed on-
line Right Size Sample Size Calculators to determine optimal sample 
sizes, which should be analyzed to generate statistically meaningful, 
sufficient, and relevant data for influenza surveillance.2,5 The user 
chooses the state or population, and based on the prevalence of in-
fluenza, the calculators generate the sample sizes with specified con-
fidence levels, margin of errors (MOEs), and a reminder that biases 
in sampling could change the result. The CDC recognizes the start of 
influenza season at a threshold of ≥10% influenza positivity among 
all specimens tested from patients with MA- ILI for two consecutive 
weeks. Calculator A utilizes this threshold to estimate the recom-
mended sample sizes needed to ascertain influenza activity, with re-
sulting information referred to as “situational awareness.” Calculator 
B determines statistically appropriate sample sizes for the detection 
of a rare/novel influenza virus.2
2.1.3 | Quality of influenza data
Considerable alternate data are readily available since NYSDOH added 
laboratory- confirmed influenza to its list of reportable communicable 
diseases in December 2004. Positive influenza laboratory results, re-
gardless of test method, are required to be reported to the NYSDOH 
6 by clinical laboratories with permits. A NYSDOH clinical laboratory 
permit must be obtained through the Clinical Laboratory Evaluation 
Program (CLEP) by laboratories performing diagnostic testing on NYS 
patients,7 the requirements for which include a quality management 
system (QMS). NYS laboratories are eligible for (i) a permit for high or 
moderate complexity testing or (ii) registration as a Limited Service 
Laboratory (LSL) to perform waived tests that are simple and consid-
ered to have minimal risk of incorrect results or cause harm. Limited 
Service Laboratorys include nursing homes, school/student health ser-
vices, dialysis facilities, ambulatory surgery centers, county health de-
partments, correctional facilities, ambulance/rescue squads, and other 
direct patient care facilities. Physician Office Laboratories (POLs), op-
erated by healthcare practitioners, only perform tests on specimens 
from their own patients and are exempt from the requirement to hold 
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a CLEP permit. Limited Service Laboratorys and POLs, with minimal 
QMS and regulatory oversight, are not required to report positive in-
fluenza results to the state health department.
2.1.4 | Reporting of influenza data in NYS
The Electronic Clinical Laboratory Reporting System (ECLRS) provides 
an electronic system for prompt and protected transmission of report-
able disease information to the NYSDOH, local health departments, 
and the NYCDOHMH.8
Clinical and commercial laboratories submit influenza- positive 
test results electronically to the NYSDOH via ECLRS. Each ECLRS 
report contains specimen- level data, including name, DOB, sex, ad-
dress, home phone, county of residence, reporting laboratory, ordering 
physician, specimen source, testing method, results, specimen col-
lection date, and report date. New York State Department of Health 
staff review the submitted data to determine whether it meets the 
case definition for laboratory- confirmed influenza, defined as a posi-
tive influenza laboratory test result with at least one of the following 
methods: culture, enzyme immunoassay (EIA), direct immunofluores-
cence assay (DFA), immunofluorescence assay (IFA), RT- PCR, immu-
nohistochemistry (IHC), or influenza virus antigen detection systems 
(IVADs, also known as rapid influenza diagnostic tests, RIDTs). If 
the case definition is met, an influenza case report is created in the 
Communicable Disease Electronic Surveillance System (CDESS). The 
system automatically deletes duplicate CDESS case reports on the 
same patient. If the Wadsworth Center tests and does not confirm 
an initial positive influenza result from another laboratory, the initial 
F IGURE  1 NYS map showing the 39 counties of 57 total outside of NYC that contribute to the ILINet and EIP influenza virologic surveillance 
networks. Counties participating in the EIP program are clustered around the cities of Albany and Rochester. The distribution of the ILINet 
primary care practitioners is indicated by number in each county and include the following practice types: pediatrics, family practice, internal 
medicine, student health, urgent care, obstetrics/gynecology, allergy and asthma, ear nose and throat, employee health, infectious disease, and 
pulmonology. Gray counties do not have providers enrolled in either the ILINet or EIP. The NYS map also depicts the 11 NREVSS laboratories 
and the 11 WHO collaborating laboratories, which include the NYS PHL in Albany and the three regional PHLs in Erie and Westchester Counties 
and NYC
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test is considered a false- positive result and the original influenza 
case report is revoked. Communicable Disease Electronic Surveillance 
System allocates ECLRS positive influenza laboratory results to dis-
ease classification codes for influenza type A or B, influenza type not 
specified, A/H1pdm09 subtype (since 2009), and H7N9 (since 2013). 
A disease classification code for influenza A/H3 subtype was added in 
October 2014 pursuant to discussions from this project.
While PHLs including Wadsworth use the CDC influenza rtRT- 
PCR panel to detect and subtype influenza viruses, clinical laborato-
ries use a variety of testing methods, which may or may not include 
subtyping. The majority of influenza molecular assays generate results 
in approximately 1- 8 hours and are capable of detecting influenza vi-
ruses with very high sensitivity and specificity; some tests also identify 
subtypes.9 Growth and isolation of influenza viruses in culture may 
take 7- 14 days or longer, while IVAD kits provide results in 15- 30 min-
utes.10 Table 1 summarizes 2014 information on testing platforms and 
assays, the number of licensed clinical laboratories using them in NYS, 
test complexity, and the influenza types/subtypes and other respira-
tory pathogens detected.
2.2 | Rare/novel influenza virus detection with NYS 
PHL data sources
Revised recommendations released in 2014 11 advised using only PHL 
data generated with molecular methods for the assessment of sample 
sizes for detection of a rare/novel influenza event. Three regional PHLs 
exist in NYS: the Erie County PHL in western NY, the NYC PHL, and 
Westchester PHL downstate. Sample sizes and confidence levels were 
evaluated with the calculators for all available data generated with the 
CDC influenza rtRT- PCR assay from Wadsworth and the regional PHLs.
Pooling state surveillance data into national aggregates produce 
large enough sample sizes to meet recommended confidence levels 
for the detection of a rare/novel influenza event. During peak season 
when influenza positivity is 20% or greater, the Right Size Roadmap 
recommends that states calculate sample sizes sufficient to have 95% 
confidence in detecting one novel virus among 700 influenza- positive 
specimens. Prior and post- peak influenza activity, when positivity is 
less than 20%, the Roadmap recommends a detection threshold of 
one novel virus of 200 influenza- positive specimens, while for off- 
season and summer periods, a threshold of one novel virus among four 
influenza positive samples is recommended.
3  | RESULTS
3.1 | Recommended sample sizes for NYS influenza 
surveillance
The goal for NYS is to obtain recommended sample sizes for the state 
population of approximately 20 million, which would ensure optimal 
detection thresholds with ≥95% confidence and ≤5% margin of error 
(MOE), for both situational awareness and rare/novel event detection 
(Table 2). Computer modeling software for situational awareness with 
Calculator A establishes ideal sample sizes using unscreened MA- ILI 
specimens. For detection of a rare/novel event, the current Calculator 
B revised late 2015 uses only Flu+ specimens tested at state PHLs.
3.2 | Sample size calculations for situational 
awareness in NYS
New York State influenza test data were compared with the recom-
mended sample sizes for situational awareness as determined with 
Calculator A (Figure 2). To avoid bias, specimens should prefer-
ably be unscreened, or a random sampling. The Wadsworth Center 
Virology Laboratory receives specimens for influenza testing from 
many sources including some that are prescreened by IVADs or other 
methods. During most weeks of peak influenza activity, sample sizes 
needed to achieve ≥95% confidence levels for situational awareness 
were obtained only with a combination of randomly submitted Flu+ 
and MA- ILI specimens. During peak season, the recommended sample 
sizes were not achieved with only MA- ILI specimens, or outside of 
peak season with Wadsworth test data alone.
The WHO/NREVSS laboratories in NYS provide additional data 
with sufficient power to meet the optimal confidence levels and MOE 
determined with Calculator A (Figure 3) during high and low influenza 
activity. While the WHO/NREVSS laboratories already transmit data 
to the CDC, the data from the WHO/NREVSS laboratories within NYS 
can still be used for state surveillance. In utilizing the WHO/NREVSS 
data to determine the true prevalence of Flu+/MA- ILI, confidence lev-
els were 99% ± ≤5% throughout the year, including off- season when 
adjusted for estimated prevalence, indicating that the WHO/NREVSS 
data are likely to provide an accurate representation of the true influ-
enza prevalence.
Alternate data for situational awareness during the 2013- 2014 
influenza season in NYS were obtained from 193 clinical laboratories, 
which reported 43 281 positive influenza laboratory results to ECLRS, 
including results of high- and moderate- complexity testing as well as 
waived testing. These results generated 37 180 positive influenza 
CDESS cases (Figure 3), which do not include negative influenza test 
results, yet are comprised of IVAD, culture, and molecular influenza 
testing methodologies. In NYS, a biphasic influenza picture occurred 
during the 2013- 2014 season with highest levels of influenza type A 
circulating in January and high levels of influenza type B circulating 
in April.
Test methods for the 2013- 2014 season included 17 426 influ-
enza test results positive by IVAD methods (40%) compared to 20 170 
positive by PCR tests (47%) (Figure 4). The majority of clinical labo-
ratories use IVAD tests for influenza. The impact of alternate data 
on situational awareness was analyzed for both rapid influenza tests 
and molecular test methods. Surpassing the situational awareness 
threshold of 137 samples to indicate the start of the influenza sea-
son, IVAD testing yielded 155 positive samples during the first week 
of December [Morbidity and Mortality Weekly Report (MMWR) week 
1349], and 219 PCR- positive samples 2 weeks later (MMWR week 
1351). However, false- positive IVAD results are of particular concern 
outside of peak influenza season when the positive predictive value of 
these tests is low.
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3.3 | Sample size calculations for rare/novel virus 
detection with NYS PHL data
For the detection of a rare/novel influenza virus, Wadsworth test 
data were compared to recommended sample sizes for NYS, aggre-
gated on a national scale, determined from Calculator B (Figure 5). 
The total number of Flu+ specimens tested at the Wadsworth Center 
was insufficient to detect a rare/novel event for influenza surveil-
lance at the recommended confidence levels. To augment detection 
of a rare/novel influenza virus, NYS regional PHL influenza rtRT- PCR 
data supplemented the Wadsworth Center rtRT- PCR data (Figure 5). 
From the last week of December 2013 through January 2014 with 
peak influenza activity, Flu+ data provided 86% to 94% confidence 
in the likelihood of detecting a novel virus present at 1/700 of cases. 
During low season, the recommended threshold for detection of a 
novel virus outside of peak season is 1/200 with a minimum Flu+ 
sample size of 37; sample sizes with 95% confidence were obtained 
for 4 of those 6 weeks (Table 2). During off- season, the recom-
mended threshold drops to ¼ with a minimum Flu+ sample size of 1. 
In fact, just 1 Flu+ sample is needed every 5 weeks per state, as 11 
Flu+ samples are needed per week for 52 states nationally (personal 
communication, Lynette Brammer, CDC). Sample sizes with 95% con-
fidence were obtained for 40 of 40 off- season weeks when counting 
1 Flu+ every 5 weeks. Thus, to contribute to national surveillance in 
TABLE  1  Influenza testing platforms used by NYS CLEP licensed clinical laboratories testing NYS specimens
Influenza Testing Platforms
Data from NYS CLEP Proficiency Testing Event Jan 2014
Molecular Nucleic Acid Detection Culture Antigen Detection
Real- time RT- PCR Typing/Subtyping Kits Virus Growth, Isolation and IFA Confirmation Influenza Virus Antigen Detection (IVAD)
Number of labs performing each assay
50 labs total 32 labs total 208 labs total
16 8 6 3 3 1 9 1 1 2 2 14 2 4 3 3 1 3 53 50 30 30 29 5 5 4 2






































































































Name of Influenza Testing Assay, Respiratory 


















































































































































































































































































































































































Influenza Type A X X X X X X X X X X X X X X X X X X X X X X X X
Influenza A/H1 seasonal X X X X X
Influenza A/H3 X X X X X
Influenza A/H1pdm09 X X X X X X X X
Influenza A/H5 X
Influenza A/H7 X
Influenza Type B X X X X X X X X X X X X X X X X X X X X
Adenovirus X X X X X X
Human coronaviruses OC43, 229E, HKU1, NL63 X X
Human metapneumovirus X X X
Human rhino/enterovirus X X X
Parainfluenza 1, 2, 3 X X X X X X
Parainfluenza 4 X X
Respiratory syncytial virus (RSV) X X X X X
RSV Type A X X X
RSV Type B X X X
aIn combination with other kits
bThe Luminex xTAG, used in 2014, did not detect influenza A/H1pdm09, human coronaviruses or parainfluenza viruses.
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detecting a rare/novel influenza virus, combined sample sizes from 
Wadsworth and the regional PHLs were sufficient to reach minimum 
confidence levels (≥85%) for recommended detection thresholds 
during peak weeks of influenza activity, and optimal (≥95%) confi-
dence for the majority of low season and all of off- season, yet not 
throughout the year.
4  | DISCUSSION
For patient samples tested at Wadsworth, the recommended sample 
size for influenza surveillance for situational awareness was achieved 
for half of the peak weeks of influenza activity. This data included 
test results from the random submission of specimens from hospital-
ized cases as well as those from primary care patients. To augment 
the total surveillance information, other data sources from clinical 
and commercial laboratories were investigated. The WHO/NREVSS- 
collaborating laboratories, geographically spread throughout NYS, 
generate considerable data for situational awareness and directly 
transmit these data to the CDC, as well as NYS. All WHO/NREVSS 
laboratories post negative as well as positive results, providing suffi-
ciently robust data for estimates of influenza prevalence. Beyond the 
WHO/NREVSS- collaborating laboratories, the remainder of the clini-
cal laboratories that report to ECLRS do not report to CDC, nor are 
TABLE  1  Influenza testing platforms used by NYS CLEP licensed clinical laboratories testing NYS specimens
Influenza Testing Platforms
Data from NYS CLEP Proficiency Testing Event Jan 2014
Molecular Nucleic Acid Detection Culture Antigen Detection
Real- time RT- PCR Typing/Subtyping Kits Virus Growth, Isolation and IFA Confirmation Influenza Virus Antigen Detection (IVAD)
Number of labs performing each assay
50 labs total 32 labs total 208 labs total
16 8 6 3 3 1 9 1 1 2 2 14 2 4 3 3 1 3 53 50 30 30 29 5 5 4 2
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Influenza Type A X X X X X X X X X X X X X X X X X X X X X X X X
Influenza A/H1 seasonal X X X X X
Influenza A/H3 X X X X X
Influenza A/H1pdm09 X X X X X X X X
Influenza A/H5 X
Influenza A/H7 X
Influenza Type B X X X X X X X X X X X X X X X X X X X X
Adenovirus X X X X X X
Human coronaviruses OC43, 229E, HKU1, NL63 X X
Human metapneumovirus X X X
Human rhino/enterovirus X X X
Parainfluenza 1, 2, 3 X X X X X X
Parainfluenza 4 X X
Respiratory syncytial virus (RSV) X X X X X
RSV Type A X X X
RSV Type B X X X
aIn combination with other kits
bThe Luminex xTAG, used in 2014, did not detect influenza A/H1pdm09, human coronaviruses or parainfluenza viruses.
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their data shared with CDC by the NYSDOH. These ECLRS/CDESS 
data consist of only influenza- positive cases, and sufficient numbers 
are not attained for situational awareness in the off- season months. 
The CDESS Flu+ cases for NYS surveillance comprise a large alternate 
data source that is not currently transmitted to the CDC and provides 
an indicator of prevailing influenza strains.
In the months preceding peak influenza activity, more samples 
were tested by IVAD than PCR, yet the reliability of the IVAD data 
is questionable. Some providers submit IVAD- positive specimens to 
the Wadsworth Center for PCR confirmation and identification of 
the subtype, particularly at the beginning of the season. A significant 
number of IVAD- positive tests are not submitted for confirmation 
by PCR testing but are still reported as CDESS- positive cases. The 
Right Size Roadmap companion document released in October 2014 
“Using Alternative Data for Influenza Virologic Surveillance” states 
“Alternative sources should ONLY be used for determining situational 
awareness. Only PHL rRT- PCR test data should be used to meet na-
tional novel influenza event detection thresholds”.11
F IGURE  2  Influenza testing performed 
during 2013- 2014 by the Wadsworth 
Center on respiratory samples, relative to 
the recommended sample size determined 
from the Right Size Roadmap Calculator 
A for situational awareness, with 95% 
confidence and 10% expected prevalence 










































































































NYS Wadsworth influenza testing
2013-2014
Wadsworth ILINet received Wadsworth EIP received
Wadsworth total tested Sample size (95% Confidence)
NYS sample sizesa
Confidence level ≥95% 
and margin of error ≤5%
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100%Percent of specimen type
Calculator A: situational awareness for seasonal influenza
 Recommended sample 
size per week
137 - - - 
 Weeks sample size 
attained by Wadsworth 
NY PHL
6 - - - 
 Weeks sample size 
attained NY PHLs & 
WHO/NREVSS data
41 - - - 
Calculator B: detection of a rare/novel influenza event
 Recommended sample 
size per week
- 130 37 1
 Weeks sample size 
attained
- 0 4 40c
 Total weeks per season - 6 6 40
aAll calculations based on population of 19 570 261.
bFlu+ = Laboratory confirmed influenza, MA- ILI = medically attended influenza- like illness.
cOff- season 30 of 40 weeks if 1Flu+/week, or more accurately 40/40 weeks with 1 Flu+ every 5 weeks.
TABLE  2 Sample sizes calculated for 
NYS using the influenza Virologic 
Surveillance Right Size roadmap calculators 
A and B for 2013- 14
     |  145ESCUYER Et al.
Wadsworth molecular data were insufficient to achieve recom-
mended confidence levels and thresholds for detection of a rare/novel 
event throughout 2013- 2014. Only the CDC RT- PCR panel used at 
the state PHLs detects all influenza subtypes commonly circulating in 
humans, as well as A/H5 and A/H7 strains with kits provided for reflex 
testing. Therefore, only the CDC assays are likely to reveal an emerg-
ing novel virus. Wadsworth and the regional NYS PHL data combined 
met the Flu+ sample sizes needed to detect a novel virus at a 1/700 
threshold with minimal (≥85%) confidence, for the five peak weeks 
of influenza activity. Desired sample sizes, thresholds, and optimal 
(≥95%) confidence levels were obtained for the majority of low sea-
son (1/200 threshold) and all of off- season (¼ threshold). To increase 
off- season influenza testing, NYSDOH issues an annual notice to NYS 
clinical laboratories, requesting submission of all clinical samples pos-
itive for influenza by any detection method during the summer to the 
Wadsworth Virology Laboratory for testing with CDC influenza rtRT- 
PCR assay.
Extensive validation studies have shown that molecular detec-
tion by rtRT- PCR is highly sensitive and specific for the detection 
and subtyping of influenza viruses.12 Large respiratory viral panel 
(RVP) assays have become increasingly popular for the testing of 
respiratory samples, despite a potential decrease in sensitivity com-
pared to single- target PCR assays. In a comparison of 11 898 re-
spiratory samples tested by the CDC influenza rtRT- PCR assay and 
the Luminex xTAG RVP, influenza A positive samples with low viral 
load were often not detected by the RVP and were mostly detected 
only by the CDC rtRT- PCR.13 Relying on RVP data alone could there-
fore introduce inaccurate positivity rates. Although sensitivity and 
specificities vary between different RVPs such as the BioFire Film 
Array, GenMark eSensor, Luminex xTAG, and the new NxTAG, a sig-
nificant advantage is the detection of multiple respiratory pathogens 
(Table 1).14
Compared to molecular and culture assays, the ease and rapidity 
of point- of- care antigen screening tests are perceived as beneficial 
for clinical management, particularly during periods of high preva-
lence.10 IVAD tests detect only the influenza virus type and do not 
distinguish the subtypes of influenza, nor would they identify a rare/
novel emerging virus. In a meta- analysis of 17 studies comparing A/
H1pdm09 detection by IVAD to that with rtRT- PCR, the estimated 
overall sensitivity of IVADs was 51% (ranging from 11% to 88%) (95% 
confidence interval) and the specificity was 98% (95% confidence 
interval).15 Another meta- analysis of 159 similar studies assessing 
IVAD performance determined assay sensitivities to average 62.3% 
(95% confidence interval) and the specificity to be 98.2% (97.5%- 
98.7% confidence interval.) Result accuracy was variable, depending 
on whether the specimen was collected from a child or an adult, as 
well as virus type and subtype.16 Thus, IVADs cannot reliably detect 
emerging influenza subtypes, and their widespread use presents a risk 
of missing the spread of a potentially pandemic strain. For influenza 
F IGURE  3  Influenza testing 
performed during 2013- 2014 by the 
Wadsworth Center, NYS regional PHLs, 
WHO/NREVSS- collaborating laboratories 
in NYS, and clinical and commercial 
laboratories with NYS permits (CDESS 
data), relative to the recommended 
sample size determined with the Right 
Size Roadmap Calculator A for situational 
awareness, with 95% confidence and 
10% expected prevalence of laboratory- 
confirmed Flu+/MA- ILI. (Sample numbers 
are reported by specimen received 
date for Wadsworth, collection date 












































































































NYS Wadsworth, PHL influenza testing, 
and alternative data 2013-2014
Wadsworth total tested NYS Regional PHLs Total # Tested
NYS WHO NREVSS Labs Total # Tested CDESS Total # Posive influenza
Sample size (95% Confidence)
F IGURE   4 For the 2013- 2014 influenza season 43 281 
total influenza positive tests were reported to ECLRS, of which 
40% were positive by IVAD and EIA, 47% positive by PCR, 11% 
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NYS Laboratory-confirmed influenza 
cases by test Type, 2013-2014 Season
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surveillance, recommended practices include the confirmation of IVAD 
results using molecular assays or cell culture at the beginning and end 
of the influenza season.
The NYSDOH has enhanced its statewide influenza surveillance by 
making laboratory- confirmed influenza reportable and developing an 
electronic reporting system. Electronic Clinical Laboratory Reporting 
System provides a mechanism for timely reporting, improves com-
pleteness and accuracy of reports, and facilitates the identification 
of emergent public health problems. Limiting the reportability of 
laboratory- confirmed influenza to clinical laboratories has ensured 
that the submitted test data have been performed under extensive 
QMSs, and provides tens of thousands of reports per season for ex-
tensive temporal and geographic coverage. During influenza season, 
the NYSDOH BCDC Influenza Surveillance Coordinator compiles a 
detailed weekly influenza report, which is posted online. This report 
includes geographic and demographic distribution of influenza cases; 
weekly and seasonal comparison of case numbers; testing and subtyp-
ing data from the WHO/NREVSS- collaborating laboratories in NYS; 
Wadsworth Center antiviral resistance data; numbers of healthcare 
facility- associated outbreaks; severity of disease; and any pediatric 
influenza- associated fatalities.17
Challenges exist in communicating the reporting requirements to 
clinical laboratories testing NYS patients. The multiple laboratory clas-
sifications (permitted, LSL, POL) and different reporting requirements 
across diseases can create confusion. During peak influenza season, 
NYSDOH Statistical Unit staff must prioritize influenza data process-
ing over other reportable diseases. Means of reporting of demographic 
data, LOINC® and SNOMED® coding, and test descriptions need to 
be standardized. The addition of codes for new strains, as they arise, 
improves the granularity and accuracy of reporting. Further, ECLRS 
reporting does not include the total number of specimens tested for 
denominator data. No other reportable communicable disease in NYS 
requires laboratories to report denominator data, which would be bur-
densome and might require a legislated regulatory change.
Multiple networks in NYS contribute to influenza surveillance on 
the state level, but only some of those networks transmit data to 
the CDC for national surveillance. Wadsworth Center data together 
with NYS alternate data sources portray a clear picture of influenza 
in the community and give confidence to the surveillance of influ-
enza viruses circulating at any time in each county or region. The 
NYS alternate data could enhance national influenza surveillance for 
situational awareness due to its volume, geographic representation 
within NYS, and reliability. During 2013- 2014, NYS experienced a 
second wave of influenza activity, mostly type B, as intense and long 
lasting as the first wave of influenza A/H1pdm09 activity. Several 
other northeast states also experienced this second wave of activity, 
but most of the United States did not. NYS was the only state in the 
United States to report widespread activity to CDC for 24 consecu-
tive weeks. Thus, the impact of the NYS alternate data is widespread, 
contributing to national and subsequently international influenza 
surveillance.
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F IGURE  5  Influenza testing performed 
during 2013- 2014 by the Wadsworth 
Center, and NYS regional PHLs. Total 
number of positives are shown relative 
to the recommended Flu+ sample sizes 
determined from the Right Size Roadmap 
Calculator B for detection of a rare/novel 
event with 95% confidence and expected 
prevalence of 30% for high season (1/700 
detection threshold), 10% for low season 
(1/200 detection threshold), and 1% for 
off- season (1/4 detection threshold). (The 
elevated specimen numbers for Wadsworth 
for weeks ending June 29, April 19, and 
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